These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. A systematic review and economic evaluation of epoetin alpha, epoetin beta and darbepoetin alpha in anaemia associated with cancer, especially that attributable to cancer treatment. Wilson J, Yao GL, Raftery J, Bohlius J, Brunskill S, Sandercock J, Bayliss S, Moss P, Stanworth S, Hyde C. Health Technol Assess; 2007 Apr; 11(13):1-202, iii-iv. PubMed ID: 17408534 [Abstract] [Full Text] [Related]
5. Erythropoietic agents in anaemic patients with cancer: a retrospective observational survey of epoetin alpha, epoetin beta and darbepoetin alpha use in routine clinical practice. Pujade-Lauraine E, Richard AJ, Sapède C, Hayward C. Oncol Rep; 2005 Oct; 14(4):1037-44. PubMed ID: 16142369 [Abstract] [Full Text] [Related]
7. A multicenter retrospective cohort study of practice patterns and clinical outcomes of the use of darbepoetin alfa and epoetin alfa for chemotherapy-induced anemia. Schwartzberg L, Shiffman R, Tomita D, Stolshek B, Rossi G, Adamson R. Clin Ther; 2003 Nov; 25(11):2781-96. PubMed ID: 14693304 [Abstract] [Full Text] [Related]
8. Treatment of chemotherapy-induced anemia in breast cancer: results of a randomized controlled trial of darbepoetin alfa 200 microg every 2 weeks versus epoetin alfa 40,000 U weekly. Senecal FM, Yee L, Gabrail N, Charu V, Tomita D, Rossi G, Schwartzberg L. Clin Breast Cancer; 2005 Dec; 6(5):446-54. PubMed ID: 16381629 [Abstract] [Full Text] [Related]
9. Effectiveness of darbepoetin alfa versus epoetin alfa for the treatment of chemotherapy induced anemia in patients with gynecologic malignancies. Case AS, Rocconi RP, Kilgore LC, Barnes MN. Gynecol Oncol; 2006 Jun; 101(3):499-502. PubMed ID: 16406064 [Abstract] [Full Text] [Related]
12. Economic evaluation of weekly epoetin alfa versus biweekly darbepoetin alfa for chemotherapy-induced anaemia: evidence from a 16-week randomised trial. Reed SD, Radeva JI, Daniel DB, Mody SH, Forlenza JB, McKenzie RS, Schulman KA. Pharmacoeconomics; 2006 Jun; 24(5):479-94. PubMed ID: 16706573 [Abstract] [Full Text] [Related]
13. Evaluating erythropoietic agents for the treatment of anaemia in the oncology setting. Gascón P. Eur J Cancer; 2005 Nov; 41(17):2601-12. PubMed ID: 16230006 [Abstract] [Full Text] [Related]
19. Clinical and economic comparison of epoetin alfa and darbepoetin alfa. Morreale A, Plowman B, DeLattre M, Boggie D, Schaefer M. Curr Med Res Opin; 2004 Mar; 20(3):381-95. PubMed ID: 15025847 [Abstract] [Full Text] [Related]
20. Conversion from epoetin alfa to darbepoetin alfa for management of anaemia in a community chronic kidney disease centre: a retrospective cohort study. Gobin J, Cernii A, McLean R, Finkelstein FO, Simon DB. Clin Drug Investig; 2011 Mar; 31(2):113-20. PubMed ID: 21067252 [Abstract] [Full Text] [Related] Page: [Next] [New Search]